Medtronic (NYSE:MDT) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Medtronic (NYSE:MDT) posted its quarterly earnings results on Tuesday. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.02, FiscalAI reports. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.The firm had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. During the same quarter in the previous year, the firm earned $1.38 EPS. Medtronic’s quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic updated its FY 2026 guidance to 5.620-5.660 EPS.

Here are the key takeaways from Medtronic’s conference call:

• Symplicity Spyral is positioned as a major growth driver with strong early demand (direct-to-consumer campaign drove a ~50x increase in site visits), expanding reimbursement (~100M covered lives) and growing clinical/physician adoption (200+ new accounts, physician finder >150).
• UltraViva tibial neurostimulation shows early commercial traction—the company has trained 500+ physicians, highlights product advantages (no imaging/sedation, same‑day activation, up to 15-year battery) and is investing in omni-channel consumer and hospital support to scale procedures.
• The Hugo surgical robot received FDA clearance for urologic procedures and already completed first U.S. installations/cases (Cleveland Clinic); Medtronic pairs Hugo with its Touch Surgery ecosystem (installations +20% sequentially, >1,000 systems globally) to drive adoption.
• The Stealth AXiS system secured FDA clearance for spinal procedures, integrating AI planning, navigation and robotics into one workflow that targets the 70% of U.S. spine cases using navigation and is expected to contribute to CST results as soon as Q4.
• Q3 revenue beat—$9.0B, +8.7% reported and +6% organic—and FY26 organic growth guidance (~5.5%) was reiterated, but margins face headwinds from tariffs (~$185M FY26) and unfavorable mix (CAS and diabetes), while FY27 EPS guidance targets high single‑digit growth with some temporary dilution from the planned diabetes separation and M&A.

Medtronic Stock Up 2.2%

MDT stock opened at $98.51 on Thursday. The business’s 50-day moving average is $99.14 and its two-hundred day moving average is $96.59. Medtronic has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The company has a market cap of $126.29 billion, a price-to-earnings ratio of 27.44, a P/E/G ratio of 2.54 and a beta of 0.71.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were issued a $0.71 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. Medtronic’s dividend payout ratio is currently 76.55%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on MDT. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. Sanford C. Bernstein boosted their price objective on shares of Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. Daiwa Securities Group lifted their target price on Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. Finally, Citigroup assumed coverage on Medtronic in a report on Tuesday, February 3rd. They set a “buy” rating and a $117.00 price target on the stock. Sixteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $111.05.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in MDT. Acumen Wealth Advisors LLC bought a new stake in shares of Medtronic during the 4th quarter valued at $29,000. Imprint Wealth LLC purchased a new position in Medtronic during the third quarter valued at $31,000. Chapman Financial Group LLC bought a new stake in Medtronic during the second quarter valued at about $37,000. JPL Wealth Management LLC bought a new stake in Medtronic during the third quarter valued at about $40,000. Finally, Caitong International Asset Management Co. Ltd increased its position in Medtronic by 96.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 454 shares of the medical technology company’s stock worth $44,000 after buying an additional 223 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q3 beat on revenue and EPS; management reaffirmed FY26 guidance (EPS range ~5.62–5.66) while highlighting strength in Cardiovascular (cardiac ablation) and Diabetes — the core growth drivers behind the move higher. Medtronic beats quarterly profit estimates
• Positive Sentiment: Commercial/technology catalysts: Medtronic completed first U.S. Hugo robotic surgical cases — a notable commercialization milestone — and received FDA clearance for Infuse bone graft in TLIF procedures, supporting medium‑term growth and product-led upside. Medtronic completes first U.S. cases with Hugo
• Neutral Sentiment: Management: Q3 call and transcripts provide detail on segment performance and investments; while results were solid, commentary showed investment spending and FX dynamics that will influence margin trajectory. Q3 earnings call transcript
• Neutral Sentiment: Product pipeline activity continues: MiniMed Flex submitted to FDA (diabetes separation plan continues) — a longer‑term structural positive but not an immediate earnings lever. MiniMed Flex submission
• Negative Sentiment: Margin and cost headwinds: company noted margin pressure from tariffs and higher costs — profit fell despite higher revenue, which tempers the upside from the top‑line beat. Profit Falls Despite Higher Revenue
• Negative Sentiment: Analyst reactions mixed and some price targets trimmed: several shops cut forecasts or nudged targets lower (JPMorgan, Baird, Leerink adjustments), reflecting more cautious medium‑term margin assumptions even as some firms reaffirm buys. JPMorgan price target lowered
• Negative Sentiment: Legal/competitive overhangs and mixed commentary: some market pieces flag litigation and competitive/legal noise (Masimo-related themes) that could add near‑term volatility to the investment case. Is Mixed Q3 Results, Robotics Win and Legal Hit Altering The Investment Case

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).